Mylan NV (NASDAQ:MYL)

38.31
Delayed Data
As of Jun 22
 -0.32 / -0.83%
Today’s Change
29.39
Today|||52-Week Range
47.82
-9.45%
Year-to-Date
Amgen's Neulasta Has a New Competitor
Jun 17 / GuruFocus News - Paid Partner Content
Company News For Jun 15, 2018
Jun 15 / Zacks.com - Paid Partner Content
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
Jun 15 / Zacks.com - Paid Partner Content
Mylan (MYL) to Get CRL Again for Generic Advair from FDA
Jun 14 / Zacks.com - Paid Partner Content
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
Jun 15 / Zacks.com - Paid Partner Content
Mylan CEO: You can't build a company in a quarter
Jun 04 / CNNMoney.com

Today’s Trading

Previous close38.63
Today’s open38.95
Day’s range38.10 - 38.99
Volume4,842,081
Average volume (3 months)4,603,200
Market cap$19.7B
Data as of 4:00pm ET, 06/22/2018

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)+17.63%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+7.06%
P/E ratio28.4
Price/Sales1.91
Price/Book1.51

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.60+0.61%
PRGOPerrigo Company PLC+0.31+0.41%
JAZZJazz Pharmaceuticals...-1.63-0.90%
ALNYAlnylam Pharmaceutic...+1.51+1.47%
Data as of 4:02pm ET, 06/22/2018

Financials

Next reporting dateAugust 9, 2018
EPS forecast (this quarter)$1.24
Annual revenue (last year)$11.9B
Annual profit (last year)$696.0M
Net profit margin5.85%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts